A potent, selective, orally active monopolar spindle 1 (MPS1) inhibitor with IC50 of 3 nM, with no activity for CDK2 and Aurora A (IC50>40 uM).

A potent, selective, orally active Mps1 (TTK) inhibitor with IC50 of 3.1 nM.

PF-1355 is a potent, selective, orally active Myeloperoxidase (MPO) inhibitor with EC50 of 1.47 uM.

A potent, selective, orally active neurokinin 3 (NK3R) antagonist for the treatment of schizophrenia.

Fezolinetant is an antagonist of the neurokinin 3 receptor (NK3R), used for the treatment of menopausal hot flushes.

A potent, selective, orally active nociceptin opioid receptor (NOP) agonist with EC50 of 12 nM, Ki of 0.3 nM.

A potent, selective, orally active orexin-2 receptor (OX2R) antagonist with pKi of 8.0 and 8.1 for human and rat OX2R, respectively.

A potent, selective, orally active p110δ/γ PI3K dual inhibitor with cellular IC50 of 0.29 and 7.1 nM, respectively.

A potent, selective, orally active p38α/p38β inhibitor with IC50 of 11.2/36.5 nM respectively, with no effect on p38γ and δ isoforms (IC50>1 uM).

A potent, selective, orally active S1P receptor-1 (S1P1) agonist with EC50 of 1.1 nM, 320-fold selectivity over S1P3.

A potent, selective, orally active S1P1 antagonist with IC50 of 2.5 nM Ca2+ mobilization assays, without activity on S1P2, S1P3 and S1P4 (IC50>10 uM).

A potent, selective, orally active somatostatin receptor SSTR3 antagonist with binding Ki of 0.66 nM, >500-fold selectivity over SSTR1/2/4/5.

A potent, selective, orally active somatostatin receptor SSTR3 antagonist with binding Ki of 2.3 nM, >2,500-fold selectivity over SSTR1/2/4/5 (IC50>5 uM).

A potent, selective, orally active TAAR1 partial agonist with Ki of 6 nM, EC50 of 23 nM (hTAAR1), 140-fold selectivity over β2 adrenergic receptors.

A potent, selective, orally active TRPM8 channel antaognist with IC50 of 0.8 nM, .

A potent, selective, orally active γ-secretase modulator with Aβ42 IC50 of 39 nM.

A potent, selective, orally active, small-molecule antagonist of human glucagon receptor with Ki of 6.66 nM.

A potent, selective, orally available CX3C chemokine receptor 1 (CX3CR1) modulator that inhibits the fractalkine-induced chemotaxis of human peripheral blood NK cells with IC50 of 4.9 nM.

A potent, selective, orally available GlyT1 inhibitor with IC50 of 1.6 nM, weakly inhibits rat GlyT2 (IC50=138 nM).

A potent, selective, orally available GlyT1 inhibitor with IC50 of 29 nM, demonstrates excellent in vivo occupancy of GlyT1 transporters in vivo..

PF-0346275 is a potent, selective, orally available GlyT1 inhibitor with Ki of 11.6 nM, without activity against GlyT2 (IC50>10 uM).

A potent, selective, orally available GPR40 agonist with EC50 of 3.7 nM.

A potent, selective, orally available GPR40 agonist with EC50 of 8 nM.

A potent, selective, orally available GPR40 agonist with EC50 of 9 nM.

A potent, selective, orally available GPR40 agonist with Ki of 15 nM, β-arrestin EC50 of 108 nM.

A potent, selective, orally available IAP antagonist with IC50 of 1.3, 2.2 and 200 nM for cIAP-1, cIAP-2 and XIAP, respectively.

A potent, selective, orally available inhibitor of both native and mutant Bcr-Abl with IC50 of 20-80 nM.

A potent, selective, orally available inhibitor of HCV NS3/4A protease with Ki of 0.05 and 0.9 nM for GT1b and 2a protease, respectively.

A potent, selective, orally available RIPK2 inhibitor with IC50 of 3 nM.

Avacopan is a potent, selective, orally availale C5aR (CD88) inhibitor with IC50 of 0.1 nM.

A potent, selective, orally bioavailable BET bromodomain inhibitor with IC50 of 7.2 and 28.2 nM for BRD4 BD2 and BRD4 BD1, respectively.

A potent, selective, orally bioavailable GPR120 agonist with EC50 of 42 nM in calcium flux assays.

JNJ-39758979 is a selective, orally active, and high-affinity histamine H4 receptor antagonist with Kis of 12.5, 5.3, and 25 nM for human, mouse, and monkey histamine H4 receptor, respectively. JNJ-39758979 functionally antagonizes histamine-induced cAMP inhibition with a pA2 of 7.9 in transfected cells. JNJ-39758979 shows good anti-inflammatory and antipruritic activity.

A potent, selective, orally bioavailable inhibitor of class I PI3K isoforms with IC50 of 52 nM/166 nM/116 nM/262 nM for p110α/β/δ/γ, respectively.

A potent, selective, orally bioavailable inhibitor of CXCR4 that efficiently inhibits SDF-1α binding to CXCR4 with IC50 of 0.61 nM.

A potent, selective, orally bioavailable inhibitor of EZH2 with Ki of < 3 nM.

A potent, selective, orally bioavailable IRAK-4 inhibitor that potently inhibits human and rat IRAK-4 activity with subnanomolar order, >30-fold selectivity over IRAK-1.

A potent, selective, orally bioavailable MDM2-p53 interaction inhibitor with HTRF IC50 of 1.1 nM, SJSA-1 EdU IC50 of 68 nM.

A potent, selective, orally bioavailable Mps1 kinase inhibitor with IC50 of 11 nM.

A potent, selective, orally bioavailable P2X7 receptor antagonist.

A potent, selective, orally bioavailable PI3Kδ inhibitor with IC50 of 2.6 nM.

SB-649868 is a potent and selective orally active orexin (OX) 1 and OX2 receptor antagonist (pKi =9.4 and 9.5 at the OX1 and OX2 receptor, respectively).

A potent, selective, peptide-mimetic PAR-1 antagonist with binding IC50 of 0.44 uM, with no effect on PAR-2, PAR-3, or PAR-4.

A potent, selective, peripherally active and orally available FAAH inhibitor for treatment of chronic prostatitis/chronic pelvic pain syndrome..

LY2033298 is a robust allosteric potentiator that is highly selective for the human M4 muscarinic acetylcholine receptor subtype. LY2033298 enhances inhibition by oxotremorine of light-induced phase shifts in hamster circadian activity rhythms.

A potent, selective, reversible and ATP-competitive inhibitor of Tpl2 kinase with IC50 of 50 nM.

A potent, selective, reversible and competitive antagonist of glucagon receptor with high binding affinity (IC(=50=6.6 nM) and functional cAMP activity (IC50=15.7 nM).

A potent, selective, reversible Cdc25 dual specificity phosphatase inhibitor with Ki of 32/96/40 nM for Cdc25A/B/C, respectively.

SB-265610 is a selective, competitive, nonpeptide and allosteric CXCR2 antagonist.

A potent, selective, reversible inhibitor of PTP SHP2 with IC50 of 5.5 uM, exhibits >3-fold selectivity for SHP2 over other PTPs.

A potent, selective, reversible rhomboid proteases inhibitor with Ki of 45 nM for GlpG .

A potent, selective, reversible, ATP-competitive Chk2 inhibitor with IC50 of 0.2 uM.

A potent, selective. covalent protein lysine methyltransferase SETD8 inhibitor with IC50 of 804 nM.

A potent, selectove δ-opioid receptor agonist with Ki of 0.16 nM, dispalys 133.5-fold and 960.5-fold selectivity over μOR and κOR respectively.

A potent, small molecule fetal hemoglobin (HbF) inducer with EC50 of 100 nM.

A potent, small molecule inhibitor of the proteasome subunit Rpn11 with IC50 of 2.5 uM..

A potent, specfic casein kinase 1δ (CK1δ) inhibitor with IC50 of 40 nM.

A potent, specfic CXCR2 antagonist that inhibits IL8 down-regulation of forskolin-induced cAMP with IC50 of 7.79 uM.

A potent, specific acyl protein thioesterase 2 (APT-2, LYPLA2) inhibitor with IC50 of 144 nM and Ki of 120 nM, >20-fold selectivity over APT-1 and serine hydrolase enzyme family.

A potent, specific and allosteric mGluR1 antagonist with IC50 of 6 nM and 1.4 nM for human and mouse mGluR1, respectively..

A potent, specific and competitive inhibitor of human neutrophil elastase with IC50 of 44 nM.

A potent, specific and competitive inhibitor of human neutrophil elastase with IC50 of 44 nM.

A potent, specific and nonlipid agonist of LPA2 receptor with EC50 of 3.3 uM, does not activate any of the other LPA GPCRs (>10 uM).

A potent, specific and orally active 5-Lipoxygenase-activating protein (FLAP) inhibitor with IC50 of 1.6 nM in FLAP binding assay.

A potent, specific and orally bioavailable soluble epoxide hydrolase (sEH) inhibitor with IC50 of 1.3 nM.

A potent, specific BMP receptor activin receptor-like kinase 3 (ALK3) antaognist with Ki of 5.4 nM.

VU 0465350 is a potent, specific BMP receptor activin receptor-like kinase 3 (ALK3) antaognist with Ki of 92.3 nM; shows no activity for ALK2/4/5, also shows affinity for TGFBR2, VEGFR2 and AMPK; blocks SMAD phosphorylation in vitro and in vivo, and enhances liver regeneration after partial hepatectomy.

A potent, specific CDC-like kinase (CLK) inhibitor with IC50 of 78, 16 and 86 nM for CLK1, 2 and4, respectively.

A potent, specific cell-active VHL E3 ubiquitin ligase inhibitor that inhibits VHL/HIF-α interaction with Kd of 90 nM in ITC assays.

A potent, specific GSK-3 inhibitor with IC50 of 5 nM and 10 nM for GSK3β and GSK3α, respectively.

A potent, specific immunoproteasome LMP7 subunit inhibitor with IC50 of 25 nM, >100-fold selectivity over β5c, β1i, β1c, β2i and β2c subunits (IC50>3 uM).

A potent, specific immunoproteasome β1i (LMP2) subunit inhibitor with IC50 of 104 nM, 144- and 10-fold selectivity over β1c and β5 subunit respectivey.

A potent, specific immunoproteasome β5 subunit inhibitor with IC50 of 17 nM, 21-fold and 13-fold selectivity for β5 over LMP7 and LMP2 subunits, respecitvely..

A potent, specific immunoproteasome β5 subunit inhibitor with IC50 of 44 nM, 105 and 225-fold selectivity over β2i and β1i subunit, respecitvely.

A potent, specific immunoproteasome β5 subunit inhibitor..

A potent, specific inhibitor of HCV NS5B polymerase and HCV replication (IC50=1.28 uM, replicon assay).

A potent, specific inhibitor of the SGK1 kinase activity, induces autophagy, apoptosis and ER stress in cancer cells.

MMV019313 (MMV 019313, MMV-019313) is a potent, specific malaria bifunctional farnesyl/geranylgeranyl diphosphate synthase (FPPS/GGPPS) inhibitor with IC50 of 330 nM; shows no activity against human FPPS or GGPPS (>200 uM); exhibits distinct modes of inhibition compared with bisphosphonates, inhibits P. falciparum growth with EC50 of 268 nM, overexpression and an S228T variant of PfFPPS/GGPPS confer resistance to MMV 019313.

A potent, specific mechanism-based human NAD(P)H: quinone oxidoreductase 1 (NQO1) inhibitor that demonstrates efficient inactivation of NQO1 at 100 nM in in cellular systems.

A potent, specific P-gp inhibitor with Kd of 5.1 nM.

A potent, specific proteasome β5 subunit inhibitor with IC50 of 0.26 uM, 7.3 and 17.3-fold selectivity over β2i and β1i subunit, respecitvely..

A potent, specific RARα agonist with Ki of 2 nM, displays no significant effects on RARγ in reporter based assays..

A potent, specific S1P2 receptor (Edg-5) antagonist with IC50 of 3 nM, with no agonistic or antagonistic activities on other S1PRs.

A potent, specific survivin inhibitor that inhibits survivin promoter activity with IC50 of 0.54 nM.

A potent, specific, allosteric and cell-active inhibitor of KSP with IC50 of 11 nM.

A potent, specific, allosteric inhibitor of KSP motor domain ATPase with Ki of 12 nM.

A potent, specific, cell-active NADPH oxidase1 (Nox1) inhibitor that strongly blocks ROS generation in HT29 cells with IC50 of 0.129 uM.

A potent, specific, competitive inhibitor of choline kinase-α (Chok-α) by targeting the choline binding site; significantly increases LC3II expression in MCF-7 and MCF-7/TAM cells, increases the size and number of autophagosome, causes MCF-7 and MCF-7/TAM

A potent, specific, irreversible NIMA-related Kinase 2 (NEK2) inhibitor with IC50 of 16.65 nM.

A potent, specific, noncompetitive dual CXCR1 and CXCR2 antagonist with IC50 of 38 nM (vs. CXCL1) and 36 nM (vs. CXCL8), respectively.

A potent, specific, orally available, ATP‑competitive inhibitor of Chk1 and Chk2 with Ki of 2.2 nM and 0.07 nM, respectively.

A potent, specific, orally bioactive small-molecule inhibitor of ubiquitin-conjugating enzyme UbcH5c with Kd of 283 nM.

A potent, specific, orally bioavailable CCR5 antagonist that blocks the binding of MIP-1α to CCR5 with IC50 of 1.4 nM.

Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide also exhibits antisecretory, antiproliferative, and proapoptotic activity. At equivalent molar concentrations, both the salt and free forms of a compound exhibit comparable biological activity. Nevertheless, the salt form (Pasireotide acetate) usually boasts enhanced water solubility and stability.

A potent, stable cyclohexapeptide somatostatin mimic that exhibits unique high-affinity binding to human somatostatin receptors (pKi=8.2/9.0/9.1/<7.0/9.9 for sst1/2/3/4/5, respectively).

A potent, state-dependent blocker of Cav2 channels that preferentially inhibits potassium-triggered calcium influx through recombinant Cav2.2 under depolarized conditions with IC50 of 0.27 uM, compared with hyperpolarized conditions (IC50>20 uM).

A potent, subtype-selective Grp94 inhibitor with Kd of 0.96 uM, 13-fold selectivity over Hsp90α.

A potent, subtype-selective mGluR5 negative allosteric modulator with Ki of 6.1 nM.

NS3861 fumarate is an agonist of nicotinic acetylcholine receptors (nAChRs) and binds with high affinity to heteromeric α3β4 nAChR. The binding Ki values of 0.62, 25, 7.8, 55 nM for α3β4, α3β2, α4β4, α4β2, respectively.

A potent, subtype-selective, orally available eIF4A3 inhibitor with IC50 of 0.14 uM.

A potential antipsychotic agent that binds selectively to D4 and 5-HT2A receptors with Ki of 3.0 and 5.8 nM, respectively.

A PP1 analog that has greater selectivity and potency for Zap-70(AS) over wild-type Zap-70, as assessed by Erk and Lat phosphorylation, as well as by proliferative responses of mature CD4+ cells.

A proton pump inhibitor that inhibits gastric acid secretion.

A proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells.

A proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells.

A proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells.

A proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells.

IPAG is a prototypic selective inhibitor of sigma1 receptor that engages the unfolded protein response and induces autophagy in cancer cells.

A PSMA (prostate-​specific membrane antigen) ligand-​tubulysin compound..

A pungent agent isolated from Zingiber officinale Roscoe, has been known to have anti-tumor and anti-inflammatory effects.

A purine scaffold casein kinase 1δ/1ε (CK1δ/ε) inhibitor with IC50 of 160/540 nM, respectively..

A quinoline antimalarial drug that is structurally related to the antiarrhythmic agent quinidine.

A quinoxaline-type tyrphostin that acts as a potent and selective inhibitor of PDGFR kinase in vitro and in Swiss 3T3 cells with IC50 of 0.3-1 uM.

A radioligand candidate for arginine vasopressin 1B (V1B) receptor that exhibits high binding affinities for human and rat V1B receptors with IC50 of 0.526 and 0.641 nM, respectively.

A RARβ/γ agonist originated from TTNPB, is also a selective inhibitor of aldo-keto reductase family member 1B10 (AKR1B10) with IC50 of 6.1 uM.

A RARβ-selective agonist that exhibits a full transcriptional agonistic activity and activating RARβ as efficiently as the reference agonist TTNPB.

A receptor adenine derivative binding membrane brain animal cell line.For the detailed information of 9-methyladenine, the solubility of 9-methyladenine in water, the solubility of 9-methyladenine in DMSO, the solubility of 9-methyladenine in PBS buffer, the animal experiment (test) of 9-methyladenine, the cell expriment (test) of 9-methyladenine, the in vivo, in vitro and clinical trial test of 9-methyladenine, the EC50, IC50,and Affinity of 9-methyladenine, Please contact DC Chemicals..

A resorcylic lactone type covalent kinase inhibitor that inhibits ALK1 with IC50 of 125 nM, also inhibits FLT3, VEGFR2, VEGFR3, MEK2 with IC50 of 1-10 nM..

A reversible and selective, direct thrombin inhibitor (DTI) with Ki value of 4.5 nM.

A rocaglate (flavagline) derivative that acts a highly specific inhibitor of the oncogenic translation program supporting MM, including key oncoproteins such as MYC, MDM2, CCND1, MAF, and MCL-1.

A rodenticide that poisons the central nervous system by uncoupling mitochondrial oxidative phosphorylation, which causes a decrease in adenosine triphosphate (ATP) synthesis..

A ruthenium complex anticancer agent that is useful for metastatic tumors and cis-platin resistant tumors.

A second generation, orally biovailable pan-genotypic HCV NS5B polymerase inhibitor with EC50 of 1-10 nM.

A second-generation antihistamine that acts as a selective H1 receptor antagonist.

A second-generation SINE, orally bioavailable Exportin 1 (XPO1,CRM1) inhibitor with markedly reduced brain penetration compared to selinexor (30-fold less).

A selctive small molecule inhibitor of the transcription factor GATA-binding protein 2 (GATA2).

K-7174 dihydrochloride is a selctive small molecule inhibitor of the transcription factor GATA-binding protein 2 (GATA2).

A selecitve small molecule toward Tec kinase-mediated tyrosine phosphorylation of FGF2 with IC50 of 8.9 uM.

Capadenoson is a selective agonist of adenosine-A1 receptor.

A selective GPR68 positive allosteric modulator (pEC50=6.83) with minimal PAM activity at the related proton-sensing GPCRs GPR4 and GPR65.

A selective inhibitor of 26S proteasome subunit Rpn11 with IC50 of 10±2 uM.

A selective inhibitor of the gelatinases MMP2 and MMP9 and MMP13 with Ki of 85, 150 and 120 nM, respectively.

A selective monoamine oxidase B (MAO-B) inhibitor with IC50 of 1.4 uM, with less potency for MT-1 and MT-2.

A selective neuronal potassium channel (KCNQ/KV7 channel) activator that also has indirect NMDA receptor antagonist and GABAA receptor modulatory properties.

SR-11237 is a selective pan retinoid X receptor (RXR) agonist with no retinoid A receptor (RAR) activity. .

A selective prostaglandin E receptor subtype 4 (EP4) antagonist with pKi of 8.5.

A selective protein phosphatase PHLPP inhibitor with IC50 of 4 uM for PP2C domain of PHLPP2.

A selective protein phosphatase PHLPP inhibitor with IC50 of 4 uM for PP2C domain of PHLPP2.

A selective renal outer medullary potassium channel (ROMK, Kir1.1) inhibitor with IC50 of 8 uM in T1+ flux assays, does not inhibit Kir7.1 at 100 uM.

A selective small molecule toward Tec kinase-mediated tyrosine phosphorylation of FGF2 with IC50 of 11.7 uM.

A selective small molecule toward Tec kinase-mediated tyrosine phosphorylation of FGF2 with IC50 of 7.0 uM.

A selective small-molecule inhibitor of tisoprenylcysteine carboxyl methyltransferase (Icmt) with IC50 <200 nM, does not inhibit other enzymes (farensyltransferase, geranylgeranyltransferase type I, and Rce1) at concentrations up to 50 uM.

A selective TLR8 agonist that induces activation of NF-κB at 0.4 uM.

A selective TRPM8 channel blocker with pEC50 of 6.91 in Ca(2+) influx assay, with no activity for TRPV4 (pEC50<4.6).

A selective α2A receptor agonist that can reduce peripheral sympathetic outflow and thus cansues a reduction in peripheral sympathetic tone.

A selective β1 receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension..

A selective, G protein-biased µ-opioid receptor agonist, does not promote the development of opioid-induced mechanical allodynia (OIMA) and rapidly reverses allodynia in vivo..

A selective, G protein-biased µ-opioid receptor agonist, does not promote the development of opioid-induced mechanical allodynia (OIMA) and rapidly reverses allodynia in vivo..

A selective, non-competitive inhibitor of the kinetoplastid proteasome, inhibits the chymotrypsin-like activity of the T. cruzi proteasome with IC50 of 35 nM.

A selective, nonpeptidic, noncompetitive BACE1 inhibitor with IC50 of 3.15 uM in cell-free assays.

A selective, orally active JAK3 inhibitor that reduces IL-2-mediated JAK3 tyrosine phosphorylation with cellular IC50 of 10-20 uM.

A selective, orally bioactive and brain permeable δ-secretase (AEP.

A selective, potent peptidyl blocker of the big conductance Ca2+-activated K+ channel (BKCa, KCa1.1, MaxiK) with IC50 of 0.25 nM.

A selective, potent peptidyl blocker of the big conductance Ca2+-activated K+ channel (BKCa, KCa1.1, MaxiK).

A selective, reversible inhibitor of MAO-A and serotonin reuptake inhibitor as an antidepressant..

A selective, reversible inhibitor of MAO-A and serotonin reuptake inhibitor as an antidepressant..

A selective, reversible, high-affinity PAI-1 inhibitor that prevents PAI-1 from inactivating tPA and uPA with similar potency (IC50=30 and 25 nM, respectively).

A selective, small molecule inhibitor of PIP5K1C with IC50 of 41 nM, does not ihibits other lipid kinases including PI3Ks.

A selective, water-soluble, in vivo long-lasting AMPA antagonist with Ki of 43 nM.

A sepecific, orally bioavailable SHIP1 activator with no effect on functional androgen, oestrogen, oestrogen-related receptor α, glucocorticoid, mineralocorticoid and progesterone receptor at 30 uM.

A serine protease inhibitor that inhibits the esterolytic activity of factor D (IC50=96 nM) and C1s (IC50=1.6 nM).

A short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD)..

A short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD)..

A simple DBCO-containing building block used to derivatize carboxyl groups in the presence of activators (e.g. EDC, or DCC) or activated esters (e.g. NHS esters) with DBCO moiety through a stable amide bond.

A small cardiogenic molecule that potently induces Nkx2.5 and a subset of other cardiac markers, including myocardin, troponin-I, and sarcomeric α-tropomyosin (SαTM) in a variety of different stem/progenitor cells.

A small cardiogenic molecule that potently induces Nkx2.5 and a subset of other cardiac markers, including myocardin, troponin-I, and sarcomeric α-tropomyosin (SαTM) in a variety of different stem/progenitor cells.

A small molecule 5-HT1A and 5-HT2A receptor antagonist and inhibitor of serotonin and dopamine reuptake, also possess affinity for the α1A- and α1B-adrenergic receptors..

A small molecule activator of S. aureus HssRS (heme sensor system) that induces endogenous heme biosynthesis by perturbing central metabolism.

A small molecule allosteric inhibitor of TREK channels with IC50 of 3.8, 1.7 and 10.3 uM for TREK-1, TREK-2 and TRAAK, respectively..

A small molecule allosteric inhibitor of TREK channels with IC50 of 5.0, 5.0 and 11.8 uM for TREK-1, TREK-2 and TRAAK, respectively..

A small molecule allosteric inhibitor of TREK channels with IC50 of 6.5, 4.4 and 15.7 uM for TREK-1, TREK-2 and TRAAK, respectively..

A small molecule anaphase-promoting complex/cyclosome (APC/C) inhibitor that binds to the APC preferentially suppresses APC/C(Cdc20) rather than APC/C(Cdh1).

A small molecule ANXA7 GTPase activity inhibitor, induces mouse ESCs differentiation to VECs.

A small molecule autophagy enhancer that induces autophagy independently of rapamycin in mammalian cells and enhances the clearance of autophagy substrates such as mutant huntingtin and A53T alpha-synuclein.

A small molecule autophagy enhancer that specificly inhibits myotubularin-related phosphatase MTMR14.

A small molecule BDNF mimetic that act as a direct and specific partial agonist of TrkB (EC50=200-500 pM), but not p75.

A small molecule binds to the EXO70 (exocyst component of 70 kDa) subunit of the exocyst complex (Kd=253 uM), resulting in inhibition of exocytosis and endosomal recycling in both plant and human cells and enhancement of plant vacuolar trafficking..

A small molecule CD4-mimetic that binds gp120 and blocks CD4 binding, inhibits HIV-1 entry with IC50 of 86.9 uM..

A small molecule CMKLR1 antagonist that inhibits chemerin-stimulated β-arrestin2 association with CMKLR1 (EC50=9.7 nM).

A small molecule cognitive enhancer that potentiates acetylcholine-mediated facilitation of inhibitory synaptic transmission in the hippocampal neurons.

A small molecule compound of prostaglandin D2（PGD2) inhibitor.

A small molecule corrector of ΔF508-CFTR with IC50 of 6.0 uM..

A small molecule Cu complexing ligand used for atom transfer radical polymerization (ATRP).

A small molecule Grb2 SH2 domain binding antagonist that synergistically enhances inhibition of K562 leukemia cell proliferation by imatinib (CI=0.774).

A small molecule inhibitor (IC50=0.3 uM) of DEAD-box polypeptide 3 (DDX3), a human host factor required for the replication of several DNA and RNA viruses.

A small molecule inhibitor of clathrin terminal domain and inhibits clathrin-mediated endocytosis.

A small molecule inhibitor of diacylglycerol kinase (DGK) with IC50 of 0.01-10 uM in isolated platelet membranes and in intact platelets.

A small molecule inhibitor of diacylglycerol kinase (DGK) with IC50 of 2.8 uM, inhibits the phosphorylation of OAG to OAPA with IC50 of 3.8 uM in intact platelets.

A small molecule inhibitor of Ezrin with Kd of 5.85 uM.

A small molecule inhibitor of guanine nucleotide exchange factor (GEF) catalytic activity that binds to SOS1 (Kd=14.7 uM) and disrupts GEF-Ras interaction.

A small molecule inhibitor of guanine nucleotide exchange factor (GEF) catalytic activity that binds to SOS1 (Kd=3.4 uM) and disrupts GEF-Ras interaction.

A small molecule inhibitor of HDM2-p53 interaction with FP IC50 of 0.7 uM.

A small molecule inhibitor of HECT-type ubiquitin ligase with IC50 of 6.8/6.3/6.9 uM for Smurf2/Nedd4/WWP1, respectively.

A small molecule inhibitor of HIV-1 entry via the CCR5 coreceptor.

A small molecule inhibitor of MDM2-p53 protein-protein interaction with IC50 of 16 uM..

A small molecule inhibitor of MDM2-p53 protein-protein interaction with IC50 of 5.3 uM in ELISA assay.

A small molecule inhibitor of NEMO (IKKγ)-ubiquitin binding with EC50 of 9.3 uM, directly binds to NEMO with Kd of 2.14 uM.

A small molecule inhibitor of polyglutamine (polyQ) aggregation in Huntington's disease neurons.

A small molecule inhibitor of PP2C that activates extensive 3' cleavage at a concentration 50-fold below that required by fluoride or CP..

A small molecule inhibitor of PSD-95/nNOS interaction with IC50 of 31 uM, without inhibiting nNOS catalytic activity.